Medico Remedies Ltd
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.61Medico Remedies Ltd demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, underpinned by decreasing debt levels and impressive growth in revenue, operating profit, and earnings per share. High returns on capital employed, equity, and assets further highlight its profitability. However, liquidity is a significant concern, with very low current, quick, and cash ratios indicating potential difficulties in meeting short-term obligations. Efficiency is also a notable weakness, with low turnover ratios suggesting challenges in asset utilization. While the company's coverage ratios are reasonable, the lack of dividend coverage is a point to consider. The company's valuation metrics are also weak. Overall, the company exhibits good long-term financial health but needs to address its short-term liquidity and operational efficiency.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsOvervalued
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio10.00
- Financial Ratio4.00
- Profitability Ratio10.00
- Efficiency Ratio4.67
- Coverage Ratio6.80
- Solvency Ratio10.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursBullish
- 4 HoursBullish
- 1 DayStrong Bullish
- 1 WeekBullish
- 1 MonthNeutral
Health Score : 6.61Medico Remedies Ltd demonstrates a mixed financial performance. The company shows strong solvency, growth, and profitability, underpinned by decreasing debt levels and impressive growth in revenue, operating profit, and earnings per share. High returns on capital employed, equity, and assets further highlight its profitability. However, liquidity is a significant concern, with very low current, quick, and cash ratios indicating potential difficulties in meeting short-term obligations. Efficiency is also a notable weakness, with low turnover ratios suggesting challenges in asset utilization. While the company's coverage ratios are reasonable, the lack of dividend coverage is a point to consider. The company's valuation metrics are also weak. Overall, the company exhibits good long-term financial health but needs to address its short-term liquidity and operational efficiency.
Overall Valuation Score
P/E RATIO (TTM)
37.09
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
37.70
P/B RATIO
5.71
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
2.53
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.86
EV/EBITDA RATIO
21.27
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹45.99 as on Jun 15, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Growth Score : 10.00The company shows strong growth. The revenue growth rate, operating profit growth rate, earnings per share growth, asset growth rate, and net income growth rate are all high, indicating robust expansion and improved profitability. This suggests the company is effectively capturing market opportunities and enhancing shareholder value.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | -0.82 | 15.7 | 3.57 | 4.14 | 36.42 |
| Operating Profit Growth Rate | 40 | 42.86 | 30 | 15.38 | 13.33 |
| Earnings Per Share (EPS) Growth | 87.1 | 50 | 14.94 | 22 | 29.51 |
| Asset Growth Rate | 1.32 | 12.99 | 10.34 | 25 | 27.5 |
| Net Income Growth Rate | 66.67 | 40 | 14.29 | 25 | 30 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial Score : 4.00The company's financial ratios are weak. The adjusted earnings per share, cash earnings per share, and book value per share are all low, indicating limited profitability and asset value on a per-share basis. While capital expenditures are well-managed, the dividend per share is low, which may not attract investors seeking income. This will affect the financial health of the company.
Adjusted Earnings Per Share (Adjusted EPS)PoorCash Earnings Per Share (Cash EPS)WeakBook Value Per SharePoorDividend Per Share (DPS)PoorCapital Expenditures (CapEx)Excellent| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 0.59 | 0.82 | 0.94 | 1.18 | 1.53 |
| Cash Earnings Per Share (Cash EPS) | 0.82 | 1.18 | 1.29 | 1.53 | 1.88 |
| Book Value Per Share | 4.35 | 5.18 | 6.24 | 7.41 | 8.94 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 3 | 0 | 0 | 0 | 4.4 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability Score : 10.00The company exhibits strong profitability. The gross profit margin, return on capital employed, return on equity, return on assets, operating margin, and net margin are all high, demonstrating efficient operations and effective use of capital. This indicates the company is generating substantial profits from its sales and investments.
Gross Profit MarginExcellentReturn on Capital Employed (ROCE)ExcellentReturn on Equity (ROE)ExcellentReturn on Assets (ROA)ExcellentOperating MarginExcellentNet MarginExcellent| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 4.13 | 5 | 6.9 | 7.95 | 6.8 |
| Return on Capital Employed (ROCE) | 15 | 21 | 21 | 21 | 23 |
| Return on Equity (ROE) | 13.51 | 15.91 | 15.09 | 15.87 | 17.11 |
| Return on Assets (ROA) | 9.09 | 11.49 | 13.54 | 12.5 | 11.11 |
| Operating Margin | 5.79 | 7.14 | 8.97 | 9.93 | 8.25 |
| Net Margin | 4.13 | 5 | 5.52 | 6.62 | 6.31 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency Score : 4.67The company's efficiency ratios present a mixed picture. While days sales in inventory and receivable days are high, indicating efficient management of inventory and receivables, the fixed asset, inventory, receivables, and capital turnover ratios are low. This suggests that the company is struggling to effectively use its assets to generate revenue, which could impact overall profitability and growth potential.
Fixed Asset Turnover RatioPoorInventory Turnover RatioPoorReceivables Turnover RatioPoorDays Sales in Inventory RatioExcellentReceivable DaysExcellentCapital Turnover RatioPoor| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 6.72 | 6.36 | 6.9 | 7.19 | 10.3 |
| Inventory Turnover Ratio | 7.03 | 7.05 | 7.5 | 6.47 | 6.74 |
| Receivables Turnover Ratio | 4.25 | 4.24 | 3.37 | 2.82 | 2.96 |
| Days Sales in Inventory Ratio | 51.92 | 51.77 | 48.67 | 56.41 | 54.15 |
| Receivable Days | 85.88 | 86.08 | 108.31 | 129.43 | 123.31 |
| Capital Turnover Ratio | 3.03 | 3.06 | 2.67 | 2.36 | 2.69 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage Score : 6.80The company's coverage ratios are mixed. The interest coverage ratio is high, indicating a strong ability to meet its interest obligations. However, the equity dividend coverage ratio is low, suggesting that the company is not providing adequate coverage for equity dividends. Overall, the company's coverage is decent.
Interest Coverage RatioExcellentEquity Dividend Coverage RatioPoor| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 7 | 11 | 12 | 15 | 10 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency Score : 10.00The company exhibits strong solvency. The debt ratio and debt-to-equity ratio are low, while the equity ratio is high, indicating a conservative capital structure and a reliance on equity rather than debt. This provides a stable financial base and reduces the risk of financial distress. This also means that company has more assets than liabilities.
Debt RatioExcellentDebt to Equity RatioExcellentEquity RatioExcellentDebt To Asset RatioExcellent| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.07 | 0.04 | 0.02 | 0.01 | 0.01 |
| Debt to Equity Ratio | 0.08 | 0.04 | 0.02 | 0.01 | 0.01 |
| Equity Ratio | 0.93 | 0.96 | 0.98 | 0.99 | 0.99 |
| Debt To Asset Ratio | 0.04 | 0.02 | 0.01 | 0.01 | 0 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity Score : 2.00The company's liquidity position is weak. The current, quick, and cash ratios are all very low, indicating a concerning inability to meet short-term obligations with its current assets. This could pose a risk if the company faces unexpected financial demands. On the positive side, the company has an operating cash flow ratio indicating it is generating sufficient cash flow from its operations.
Current RatioPoorQuick RatioPoorCash RatioPoorOperating Cash Flow RatioPoor| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.56 | 1.52 | 1.71 | 1.69 | 1.66 |
| Quick Ratio | 1.09 | 1.05 | 1.33 | 1.21 | 1.28 |
| Cash Ratio | 0.05 | 0.02 | 0 | 0.02 | 0.03 |
| Operating Cash Flow Ratio | 0.16 | 0.19 | 0.05 | 0.09 | 0.08 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 2 | Kilitch Drugs (India) Ltd | 6.61 | 21.54 | Neutral | 37.00 | 9.27 | 30.00 |
| 3 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 4 | SMS Lifesciences India Ltd | 6.59 | 21.20 | Undervalued | 45.00 | 70.68 | 19.00 |
| 5 | Infinium Pharmachem Ltd | 6.42 | 26.90 | Neutral | 22.00 | 6.43 | 14.00 |
| 6 | Medicamen Biotech Ltd | 5.73 | 32.19 | Neutral | 20.00 | 6.94 | 10.00 |
| 7 | Aarey Drugs & Pharmaceuticals Ltd | 5.73 | 59.71 | Neutral | 7.00 | 1.40 | 4.00 |
| 8 | Albert David Ltd | 5.63 | -272.47 | Neutral | 5.00 | -2.62 | -1.00 |
| 9 | BPL Ltd | 5.46 | -31.11 | Neutral | -4.82 | -3.00 | -8.55 |
| 10 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 11 | Lyka Labs Ltd | 4.77 | -23.98 | Neutral | -4.00 | -9.05 | -10.00 |
| 12 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
Balanced ManagementThe management of Medico Remedies demonstrates a mixed performance. The company exhibits strong profit growth and improving ROCE, indicating effective capital utilization. However, sales growth consistency and an increasing cash conversion cycle are concerns. The promoter holding has decreased, which may raise concerns among investors. Overall, while the company shows promise in profitability and returns, strategic adjustments may be needed.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Profit Growth | 22% (TTM) | Strong profit growth indicates efficient management of profitability. |
| Return on Capital Employed (ROCE) | 21% (Current) | Capital is being used productively. | |
| CONS | Sales Growth | 4% (TTM) | Sales growth is inconsistent. |
| Cash Conversion Cycle | 111 Days (Current) | Cash conversion cycle is increasing. |
Financial Performance & GrowthAverageCapital Efficiency & ReturnsGoodFinancial Health & PrudenceAverageShareholding & Ownership StructureAverageFinancial Performance & Growth
Medico Remedies demonstrates inconsistent financial performance. While the compounded profit growth shows a positive trend, sales growth is not consistent. The recent TTM sales growth is at 4%, while profit growth is at 22%. Quarterly sales have fluctuated, with YOY Sales Growth % varying from -23.37% to 47.62%. Operating Profit Margin (OPM) also shows variability, ranging from -0.54% to 16.13% quarterly. This inconsistency suggests potential challenges in maintaining stable revenue and profitability.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Compounded Sales Growth (%) | N/A | N/A | N/A | 16.05% | 3.19% | 4.15% |
| Compounded Profit Growth (%) | N/A | N/A | N/A | 28% | 27% | 25% |
Capital Efficiency & Returns
Medico Remedies shows good capital efficiency and returns. The Return on Capital Employed (ROCE) is consistently above 20% in recent years (21% currently). Return on Equity (ROE) is also strong at 17.23%. These metrics indicate that the company is effectively utilizing its capital and generating good returns for shareholders. However, the Cash Conversion Cycle has increased to 111 days as of March 2025, indicating potential inefficiencies in working capital management.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROCE (%) | ~11% | ~9% | ~12% | 21% | 21% | 21% |
Financial Health & Prudence
Medico Remedies exhibits a mixed financial health profile. The Debt/Equity ratio can be derived from the Balance Sheet data. As of March 2025, the company has borrowings of ₹15 Cr against an equity capital of ₹17 Cr and reserves of ₹46 Cr. The company consistently shares profits, as indicated by its dividend payout history. However, in recent years, the dividend payout % has been 0%.
| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Borrowings (₹ Cr) | ~10 | ~15 | ~15 | 10 | 8 | 15 |
Shareholding & Ownership Structure
The shareholding pattern of Medico Remedies indicates shifts in ownership structure. Promoter holding has decreased from 73.34% to 63.79% as of March 2025. FII holding is minimal at 0.11% as of March 2025, and DII holding is also very low at 0.01%. Public holding has increased to 36.08% as of March 2025. The number of shareholders has increased over the years, reaching 15,424 in March 2025. The decrease in promoter holding and increase in public holding may raise concerns about the alignment of interests.
| Metric | Mar 2018-Mar 2020 | Mar 2021-Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Promoter Holding (%) | 73.34% | 73.34% | 73.34% | 63.79% |
| FII Holding (%) | 0.00% | ~0.2% | 0.29% | 0.11% |
Balanced RiskMedico Remedies faces a moderate risk profile. The company exhibits segment performance volatility through fluctuating quarterly sales and profit growth. The shareholding pattern also shows potential instability with a decreasing promoter holding. These factors collectively contribute to an 'Orange' risk assessment.
Segment performance volatilityAverageShareholding & Ownership StructureAverageSegment performance volatility
Medico Remedies experiences volatility in its segment performance, as evidenced by fluctuating quarterly results. The YOY Sales Growth % varies significantly, ranging from -23.37% to 47.62%. Similarly, the YOY Profit Growth % fluctuates from -36.21% to 80.69%. This variability indicates potential challenges in maintaining consistent financial performance across different periods.
Shareholding & Ownership Structure
The shareholding pattern of Medico Remedies indicates shifts in ownership structure. Promoter holding has decreased from 73.34% to 63.79% as of March 2025. FII holding is minimal at 0.11% as of March 2025, and DII holding is also very low at 0.01%. Public holding has increased to 36.08% as of March 2025. The decrease in promoter holding and increase in public holding may raise concerns about the alignment of interests.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1053.13Bullish
- SMA 2053.06Bullish
- SMA 5051.32Bullish
- EMA 1053.25Bullish
- EMA 2052.84Bullish
- EMA 5051.69Bullish
- DEMA 1053.60Bearish
- DEMA 2053.66Bearish
- DEMA 5053.19Bullish
- TEMA 1053.62Bearish
- TEMA 2053.62Bearish
- TEMA 5053.80Bearish
- MACD0.59Bearish
- ADX23.41Weak Trend
- IndicatorValueSignal
- RSI60.46Neutral
- CCI109.06Overbought
- ROC 91.25Bullish
- ROC 142.02Bullish
- ROC 252.98Bullish
- Stoch K84.54Overbought
- Stoch D76.60Neutral
- IndicatorValueSignal
- BB Upper54.04Neutral
- BB Middle53.06Neutral
- BB Lower52.08Neutral
- ATR0.97Low Volatility
- IndicatorValueSignal
- MFI62.68Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1053.08Bullish
- SMA 2052.14Bullish
- SMA 5050.20Bullish
- EMA 1052.98Bullish
- EMA 2052.26Bullish
- EMA 5050.86Bullish
- DEMA 1053.61Bearish
- DEMA 2053.55Bullish
- DEMA 5052.47Bullish
- TEMA 1053.51Bullish
- TEMA 2053.83Bearish
- TEMA 5053.03Bullish
- MACD0.95Bullish
- ADX28.19Strong Trend
- IndicatorValueSignal
- RSI65.80Neutral
- CCI78.79Neutral
- ROC 9-0.15Bearish
- ROC 143.88Bullish
- ROC 257.33Bullish
- Stoch K78.19Neutral
- Stoch D75.82Neutral
- IndicatorValueSignal
- BB Upper55.04Neutral
- BB Middle52.14Neutral
- BB Lower49.23Neutral
- ATR1.22Low Volatility
- IndicatorValueSignal
- MFI34.50Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1052.56Bullish
- SMA 2050.98Bullish
- SMA 5049.77Bullish
- EMA 1052.52Bullish
- EMA 2051.45Bullish
- EMA 5049.61Bullish
- DEMA 1053.72Bearish
- DEMA 2053.03Bullish
- DEMA 5052.46Bullish
- TEMA 1053.89Bearish
- TEMA 2053.69Bearish
- TEMA 50N/AN/A
- MACD1.26Bullish
- ADX32.88Strong Trend
- IndicatorValueSignal
- RSI65.62Neutral
- CCI110.15Overbought
- ROC 97.38Bullish
- ROC 148.16Bullish
- ROC 257.66Bullish
- Stoch K84.97Overbought
- Stoch D81.76Overbought
- IndicatorValueSignal
- BB Upper54.80Neutral
- BB Middle50.98Neutral
- BB Lower47.16Neutral
- ATR1.67Low Volatility
- IndicatorValueSignal
- MFI53.37Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1050.83Bullish
- SMA 2049.85Bullish
- SMA 5046.47Bullish
- SMA 10043.90Bullish
- SMA 20051.06Bullish
- EMA 1051.32Bullish
- EMA 2050.17Bullish
- EMA 5047.69Bullish
- EMA 10047.00Bullish
- EMA 20048.63Bullish
- DEMA 1052.64Bullish
- DEMA 2052.15Bullish
- DEMA 5050.22Bullish
- DEMA 10046.13Bullish
- DEMA 20045.05Bullish
- TEMA 1053.18Bullish
- TEMA 2052.25Bullish
- TEMA 5052.85Bullish
- TEMA 10048.28Bullish
- TEMA 20044.99Bullish
- MACD1.50Bullish
- ADX27.62Strong Trend
- IndicatorValueSignal
- RSI68.84Neutral
- CCI176.73Overbought
- ROC 145.66Bullish
- ROC 254.73Bullish
- Stoch K86.75Overbought
- Stoch D85.47Overbought
- IndicatorValueSignal
- BB Upper53.25Neutral
- BB Middle49.85Neutral
- BB Lower46.46Neutral
- ATR2.26Low Volatility
- IndicatorValueSignal
- MFI48.56Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 2043.11Bullish
- SMA 5051.55Bearish
- EMA 2046.49Bullish
- EMA 5049.03Bullish
- DEMA 2045.72Bullish
- DEMA 5044.91Bullish
- TEMA 2047.89Bullish
- TEMA 5044.46Bullish
- MACD-0.06Bullish
- ADX23.21Weak Trend
- IndicatorValueSignal
- RSI51.65Neutral
- CCI-13.31Neutral
- ROC 1429.26Bullish
- ROC 25-9.28Bearish
- Stoch K80.64Overbought
- Stoch D77.91Neutral
- IndicatorValueSignal
- BB Upper52.47Neutral
- BB Middle43.11Neutral
- BB Lower33.74Neutral
- ATR5.08Low Volatility
- IndicatorValueSignal
- MFI84.09Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 645.52Bullish
- SMA 1251.30Bearish
- SMA 2454.63Bearish
- EMA 647.42Bullish
- EMA 1249.46Bullish
- EMA 2451.81Bearish
- DEMA 646.07Bullish
- DEMA 1245.81Bullish
- DEMA 24N/AN/A
- TEMA 647.11Bullish
- TEMA 1245.50Bullish
- TEMA 24N/AN/A
- MACDN/AN/A
- ADX22.14Weak Trend
- IndicatorValueSignal
- RSI54.31Neutral
- CCIN/AN/A
- ROC 25-28.19Bearish
- ROC 50N/AN/A
- Stoch KN/AN/A
- Stoch DN/AN/A
- IndicatorValueSignal
- BB Upper66.28Neutral
- BB Middle49.00Neutral
- BB Lower31.73Neutral
- ATR13.32Low Volatility
- IndicatorValueSignal
- MFI44.12Neutral